Drug intelligence / Profile preview

rhenium-186 + triamcinolone hexacetonide

Development stage: Unknown
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intraarticular

Overview

Rhenium-186 + triamcinolone hexacetonide is a combination therapy used for radiosynoviorthesis (radiation synovectomy) in rheumatoid arthritis. This combination consists of the radiopharmaceutical rhenium-186 and the corticosteroid triamcinolone hexacetonide. Clinical studies have shown that this combination provides better clinical results and slower progression in radiological destruction compared to either component used alone. The treatment is administered via intra-articular injection into affected joints such as shoulder, elbow, wrist, hip, and ankle joints.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on rhenium-186 + triamcinolone hexacetonide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rhenium-186 + triamcinolone hexacetonide.

Explore the full profile